All Updates

All Updates

icon
Filter
Product updates
NeoGenomics unveils new lung solution and hematopathology services portfolio
Precision Medicine
May 28, 2024
This week:
Funding
GrayMatter Robotics raises USD 45 million in Series B funding to accelerate AI-powered robotics solutions
Smart Factory
Yesterday
Funding
Vecna Robotics raises USD 100 million in Series C funding; appoints new COO
Logistics Tech
Yesterday
Funding
Vecna Robotics raises USD 100 million in Series C funding; appoints new COO
Smart Factory
Yesterday
Funding
FairNow raises USD 3.5 million to advance AI governance solutions
Generative AI Infrastructure
Yesterday
Partnerships
Gravitics develops testing gauntlet for larger spacecraft in collaboration with NASA
Space Travel and Exploration Tech
Yesterday
M&A
knownwell acquires Alfie Health to integrate AI in primary and obesity care services
Telehealth
Yesterday
Funding
Pomelo Care raises USD 46 million in Series B funding to expand virtual maternal care
Telehealth
Yesterday
Funding
Isar Aerospace raises EUR 65 million, backed by NATO Innovation Fund
Space Travel and Exploration Tech
Yesterday
Product updates
Beyond Meat releases new Beyond Sausage, expanding its Beyond IV product line
Plant-based Meat
Yesterday
Product updates
Funding
SurrealDB raises USD 20 million in Series A; launches beta version of Surreal Cloud
Data Infrastructure & Analytics
Yesterday
Precision Medicine

Precision Medicine

May 28, 2024

NeoGenomics unveils new lung solution and hematopathology services portfolio

Product updates

  • NeoGenomics has unveiled its new comprehensive lung solution and COMPASS Hematopathology Services portfolio. The demonstration for both products will occur at the upcoming American Society of Clinical Oncology conference to be held between May 31 and June 4.

  • NeoGenomics' new comprehensive lung offering is designed for complementary tissue and liquid biopsy testing, providing precise diagnosis, therapy selection, and clinical trial options. COMPASS is a portfolio of sample diagnostics services for hematological malignancies, including over 100 subtypes of leukemias, lymphomas, and myelomas. It provides an all-in-one assessment with actionable diagnostic and prognostic information tailored to patients’ needs. These offerings enable appropriate test selection for precise patient care in light of increasing FDA-approved targeted therapies and immunotherapies.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.